Trials / Unknown
UnknownNCT03903406
Quality of Life, Symptoms and Treatment Satisfaction in Adult Patients With Relapsed and/or Refractory Multiple Myeloma, Receiving Ixazomib (Ninlaro®) in Combination With Lenalidomide and Dexamethasone in a Real World Setting: Pilot Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 40 (estimated)
- Sponsor
- Multinational Center for Quality of Life Research, Russia · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this pilot study is to examine changes in patient-reported outcomes in patients with RRMM receiving triple therapy with ixazomib in combination with LenDex in a real world setting as well as to analyze clinical outcomes and safety of this treatment modality.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ixazomib in combination with lenalidomide and dexamethasone | Patients with RRMM who have received at least one prior therapy will receive Ixazomib in combination with lenalidomide and dexamethasone within the routine clinical practice in accordance with prescription. Duration of therapy - until disease progression or unacceptable toxicity. |
Timeline
- Start date
- 2019-05-01
- Primary completion
- 2021-11-01
- Completion
- 2021-11-01
- First posted
- 2019-04-04
- Last updated
- 2019-04-04
Source: ClinicalTrials.gov record NCT03903406. Inclusion in this directory is not an endorsement.